Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NT-I7 + Nivolumab in Advanced Gastric/GEJ/Esophageal Cancer
NCT04594811Phase 1Terminated
- Sponsor
- NeoImmuneTech
- Start
- Jan 2021
- Primary completion
- May 2023
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 2
01
Overview
Phase 1, open-label trial of efineptakin alfa in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and esophageal adenocarcinoma (EAC) (2 arms), sponsored by NeoImmuneTech. Primary endpoints: Treatment-Emergent Adverse Events up to 1 year, Grade >= 3 Adverse Events up to 1 year and 3 more. Started Jan 2021; status: terminated.
02
Drugs
efineptakin alfa
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NCT04594811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04594811.